James P. Nataro, MD, PhD
Degree(s): MD, PhD, MBA, FAAP
Graduate School: University of Maryland School of Medicine
Primary Appointment: Professor, Pediatrics
Pathogenesis of diarrheagenic Escherichia coli and Shigella.
Email Address: email@example.com
Dr. Nataro’s multi-disciplinary research program focuses on enteric bacterial infections, principally diarrheagenic E. coli and Shigella spp. His seminal observations include the discovery of enteroaggregative and diffusely adherent E. coli pathotypes, the introduction of the first molecular probe for enteropathogenic E. coli, the discovery of a large number of virulence factors and mechanisms, and the construction of several vaccine candidates. He has made pivotal contributions to understanding the roles of diarrheagenic E. coli in human disease.
Dr. Nataro has trained a large number of undergraduate, graduate, medical (including three MD/PhD students), as well as many post-doctoral fellows and junior faculty. While Head, Division of Infectious Diseases and Tropical Pediatrics at the University of Maryland, he mentored several young faculty to their first NIH awards.
Taniuchi M, Walters CC, Gratz J, Maro A, Kumburu H, Serichantalergs O, Sethabutr O, Bodhidatta L, Kibiki G, Toney DM, Berkeley L, Nataro JP, Houpt ER. Development of a multiplex polymerase chain reaction assay for diarrheagenic Escherichia coli and Shigella spp. and its evaluation on colonies, culture broths, and stool. Diagn Microbiol Infect Dis. 2012 Jun;73(2):121-8. doi: 10.1016/j.diagmicrobio.2012.03.008. Epub 2012 Apr 25.
Ruiz-Perez F, Wahid R, Faherty CS, Kolappaswamy K, Rodriguez L, Santiago A, Murphy E, Cross A, Sztein MB, Nataro JP. Serine protease autotransporters from Shigella flexneri and pathogenic Escherichia coli target a broad range of leukocyte glycoproteins. Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12881-6. doi: 10.1073/pnas.1101006108. Epub 2011 Jul 18.
Shamir ER, Warthan M, Brown SP, Nataro JP, Guerrant RL, Hoffman PS. Nitazoxanide inhibits biofilm production and hemagglutination by enteroaggregative Escherichia coli strains by blocking assembly of AafA fimbriae. Antimicrob Agents Chemother. 2010 Apr;54(4):1526-33. doi: 10.1128/AAC.01279-09. Epub 2010 Jan 19.
|Office Address:||PO Box 800386,|